Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Cutia Therapeutics

Cutia Therapeutics

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)12.14
  • Today's Change-0.80 / -6.18%
  • Shares traded750.40k
  • 1 Year change-39.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cutia Therapeutics is a China-based company mainly engaged in the research and development and manufacture of dermatological biological drugs. The Company is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The Company is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The Company conducts its businesses in the domestic market and overseas markets.

  • Revenue in HKD (TTM)217.21m
  • Net income in HKD-572.76m
  • Incorporated2019
  • Employees360.00
  • Location
    Cutia Therapeutics436 Heng Feng RoadJingan District, 20/F, Huanzhi BuildingSHANGHAI ChinaCHN
  • Websitehttps://www.cutiatx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
VIVA Biotech Holdings2.18bn-347.36k2.08bn2.04k--0.50208.190.9559-0.0055-0.00551.061.930.26035.265.181,049,316.000.4017-1.390.5601-1.6833.6634.811.54-5.441.463.190.2884---9.4259.3178.03--31.98--
Golden Throat Holdings Group Co Ltd1.10bn286.42m2.37bn860.008.261.697.192.150.38740.38741.491.900.49943.234.071,264,845.0013.0111.0019.2615.6372.2972.7926.0624.671.9337.740.281483.15-3.096.73-11.0419.61-32.1338.94
Cutia Therapeutics217.21m-572.76m3.96bn360.00--3.04--18.23-1.88-1.880.71364.260.12062.316.93728,907.80-31.81---35.82--50.33---263.68--4.82--0.1818--1,110.83---253.30------
Jiangsu Recbio Technology Co Ltd0.00-599.19m4.12bn507.00--4.48-----1.25-1.250.001.910.00----0.00-25.33---32.84----------0.9619--0.4548------20.86------
Ocumension Therapeutics338.94m-352.52m4.58bn477.00--1.28--13.53-0.5379-0.53790.5174.360.1032.402.48763,383.40-10.71-38.78-11.55-41.4758.2962.30-104.01-975.825.00--0.0055--54.99--5.68--319.66--
Beijing Luzhu Biotechnology Co Ltd0.00-305.78m4.87bn148.00--4.76-----1.51-1.510.005.090.00----0.00-23.80---25.44----------5.91--0.0296------65.62------
Shandong Boan Biotechnology Co Ltd786.30m67.51m4.88bn777.0068.723.0534.086.210.13260.13261.542.990.30691.102.60967,157.302.63--3.43--74.10--8.59--1.034.010.3369--19.80--64.02------
Data as of Nov 01 2024. Currency figures normalised to Cutia Therapeutics's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

8.76%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 28 May 202413.30m4.37%
Harvest Global Investments Ltd.as of 09 Jun 20237.16m2.35%
FIL Investment Management (Singapore) Ltd.as of 28 May 20244.14m1.36%
FIL Investments Internationalas of 31 Aug 20241.81m0.59%
Bosera Asset Management Co., Ltd.as of 30 Jun 2024205.60k0.07%
Huashang Fund Management Co., Ltd.as of 30 Jun 202467.40k0.02%
Harvest Fund Management Co., Ltd.as of 30 Jun 20245.40k0.00%
E Fund Management Co., Ltd.as of 30 Jun 20244.14k0.00%
FIL Investment Advisors (UK) Ltd.as of 31 Oct 20231.000.00%
More ▼
Data from 30 Jun 2024 - 23 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.